Agape Pain Management & Anesthesia Llc

CLIA Laboratory Citation Details

2
Total Citations
12
Total Deficiencyies
4
Unique D-Tags
CMS Certification Number 32D2095249
Address 2170 E Lohman Ave Suite C, Las Cruces, NM, 88001
City Las Cruces
State NM
Zip Code88001
Phone575 449-7002
Lab DirectorWENBING CHEN

Citation History (2 surveys)

Survey - May 14, 2025

Survey Type: Standard

Survey Event ID: EM6N11

Deficiency Tags: D0000 D5401 D5411 D0000 D5401 D5411

Summary:

Summary Statement of Deficiencies D0000 An onsite recertification survey conducted on May 14, 2025, at Agape Pain Management & Anesthesia found the laboratory to be out of compliance with the CLIA regulations found at 42 CFR, Part 493 Laboratory Requirements. D5401 PROCEDURE MANUAL CFR(s): 493.1251(a) (a) A written procedures manual for all tests, assays, and examinations performed by the laboratory must be available to, and followed by, laboratory personnel. Textbooks may supplement but not replace the laboratory's written procedures for testing or examining specimens. This STANDARD is not met as evidenced by: Based on review the laboratory's "Specimen Rejection Criteria" and "Laboratory Record Retention" policies, lack of documentation, and interview with the Technical Consultant (TC), the laboratory failed to follow its own policy to maintain a log for rejected specimens in 2024 and 2025. Findings include: 1. Review of the laboratory's "Specimen Rejection Criteria" policy stated, "All rejected specimens will have the reason for rejection documented in the specific laboratory log." 2. Review of the laboratory's "Laboratory Record Retention" policy stated lab logs and worksheets are "stored and readily accessible for 2 (two) years". 3. A request was made for documentation showing records of rejected specimens, none was provided. 4. An interview on 05/14/2025 at 2:11 pm with TC confirmed the above findings. 5. The laboratory reports 2700 toxicology tests annually. D5411 TEST SYSTEMS, EQUIPMENT, INSTRUMENTS, REAGENT CFR(s): 493.1252(a) (a) Test systems must be selected by the laboratory. The testing must be performed following the manufacturer's instructions and in a manner that provides test results Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 2 -- within the laboratory's stated performance specifications for each test system as determined under 493.1253. This STANDARD is not met as evidenced by: I. Based on review of Immunalysis Methamphetamine Urine HEIA (MUH) manufacturer's instructions (MI), Immunalysis SEFRIA Fentanyl Urine (SFU) MI, lack of documentation, and interview with the Technical Consultant (TC), the laboratory failed to follow the manufacturer's instructions to centrifuge highly turbid urine specimens before toxicology testing in 2024 and 2025. Findings include: 1. Review of MUH MI and SFU MI indicated "Highly turbid specimens should be centrifuged before analysis." 2. The laboratory was asked to provide a policy that covers processing highly turbid urine specimens for methamphetamine and fentanyl testing, none was provided. 3. The laboratory was asked to provide evidence that highly turbid urine specimens are centrifuged before analysis, none was provided. 4. During an interview on 05/14/2025 at 2:03 pm, the TC stated the laboratory "does not have a low-speed centrifuge for processing turbid specimens", which confirms the above findings. 5. The laboratory reports 2,700 toxicology tests annually. II. Based on review of IMMTOX 270 manufacturer's instructions, the laboratory's "Laboratory Maintenance" policy, the laboratory's temperatures and humidity log, and interview with the Technical Consultant (TC) the laboratory failed to follow manufacturer's instructions by failing to maintain humidity requirements for the IMMTOX 270 for three of three months reviewed in 2024. Findings Include: 1. Review of IMMTOX 270 manufacturer's instructions stated, "Room humidity should be 35-80%RH, and no condensation." 2. Review of the laboratory's "Laboratory Maintenance" policy indicated a room humidity requirement of 15-85% 3. A random review of the laboratory's temperature and humidity log showed the room humidity was below 35% for 15 of 15 recorded days in February 2024, 11 of 11 recorded days in June 2024, and 17 of 17 days in November 2024. 4. Interview on 05/14/2025 at 10:20 am with the TC confirmed the above findings. 5. The laboratory reports 2,700 toxicology tests annually. -- 2 of 2 --

πŸ”’ Unlock Deficiency Summary

Get full access to the detailed deficiency summary for this facility

One-time payment β€’ Lifetime access

Survey - March 6, 2024

Survey Type: Standard

Survey Event ID: YVKX11

Deficiency Tags: D0000 D5401 D5401 D0000 D6065 D6065

Summary:

Summary Statement of Deficiencies D0000 An onsite recertification survey conducted on March 6, 2024, at Agape Pain Management & Anesthesia LLC found the laboratory to be in compliance with the CLIA regulations found at 42 CFR, Part 493 Laboratory Requirements, with standard deficiencies cited. D5401 PROCEDURE MANUAL CFR(s): 493.1251(a) A written procedures manual for all tests, assays, and examinations performed by the laboratory must be available to, and followed by, laboratory personnel. Textbooks may supplement but not replace the laboratory's written procedures for testing or examining specimens. This STANDARD is not met as evidenced by: Based on review of ImmTox 270 Maintenance Guide, ImmTox270 Periodic Maintenance Log, and interview, the laboratory failed to follow procedures for performing required weekly maintenance on the ImmTox270 for 6 of 18 weeks from November 2023 through February 2024. Findings Included: 1. Review of the ImmTox 270 Maintenance Guide lists the following required maintenance to be done weekly: - ImmTox270 and LIS Backup - Special wash (probes and cells) - Probe Wash 2. Review of the ImmTox270 Periodic Maintenance Log revealed the following weekly maintenance being performed: - ImmTox270 and LIS Backup - Special wash (probes and cells) - Probe Wash - Clean Water Reservoir -Clean Waste Reservoir 3. Review of ImmTox270 Periodic Maintenance Log also revealed the following weeks where weekly maintenance was not performed. 1. November 13th - 17th 2023 2.December 18th - 27th 2023 3. December 25th - 29th 2023 4. January 1st - 5th 2024 5. January 15th - 19th 2024 6. February 5th - 9th 2024 4. Interview on March 6th, 2024 at 2:30 pm with the general supervisor confirmed the findings. D6065 TESTING PERSONNEL QUALIFICATIONS Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 2 -- CFR(s): 493.1423(b)(1)(2)(3)(4)(i) (b) Meet one of the following requirements: (b)(1) Be a doctor of medicine or doctor of osteopathy licensed to practice medicine or osteopathy in the State in which the laboratory is located or have earned a doctoral, master's, or bachelor's degree in a chemical, physical, biological or clinical laboratory science, or medical technology from an accredited institution; or (b)(2) Have earned an associate degree in a chemical, physical or biological science or medical laboratory technology from an accredited institution; or (b)(3) Be a high school graduate or equivalent and have successfully completed an official military medical laboratory procedures course of at least 50 weeks duration and have held the military enlisted occupational specialty of Medical Laboratory Specialist (Laboratory Technician); or (b)(4)(i) Have earned a high school diploma or equivalent; and This STANDARD is not met as evidenced by: Based on review of CMS 209 form and interview, the laboratory failed to provide education records for 1 (TP #4) of 7 testing personnel (TP). Findings include: 1. Review of CMS 209 form listed 7 testing personnel. 2. Education records were requested for testing personnel #4. None were provided. 3. Interview on March 6th, 2024 at 10:30 am with the general supervisor confirmed the findings. -- 2 of 2 --

πŸ”’ Unlock Deficiency Summary

Get full access to the detailed deficiency summary for this facility

One-time payment β€’ Lifetime access